Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 1 to 6 Years) With APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed by an Open-label Long-term Extension

NCT05693129 is registered in ClinicalTrials.gov with Pharming Technologies B.V. as lead sponsor.

NCT NCT05693129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05693129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 1 to 6 Years) With APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed by an Open-label Long-term Extension
Lead sponsor
Pharming Technologies B.V.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 30, 2023
Completion date
October 28, 2028
Enrollment
16 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

apds